Zinc Chloride
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Zinc Chloride
- Zinc Chloride: From Trace Element Supplementation to Severe Nonproliferative Diabetic Retinopathy
Zinc Chloride: From Trace Element Supplementation to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Zinc chloride is a trace element used in parenteral nutrition products, and it is registered in Singapore in three infusion concentrates. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, but no clinical trials and no publications currently support this specific prediction. The evidence rests on model prediction alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration records (the products are infusion concentrates containing zinc) |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, zinc chloride is a source of zinc, an essential trace element, and it is used in infusion concentrates. Zinc is a cofactor of antioxidant enzymes such as Cu/Zn-superoxide dismutase, so it may plausibly protect the retina against oxidative stress.
Oxidative stress is a recognised driver of diabetic retinopathy. This gives a plausible but unproven link between zinc and the predicted disease. No clinical evidence was compiled for this specific stage (severe nonproliferative disease), so the link remains speculative.
The next-ranked prediction, diabetic retinopathy (score 98.89%), has one supporting animal study, described below.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No literature was compiled for the top-ranked prediction. For the closely related prediction of general diabetic retinopathy, one preclinical study was found:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15541754 | 2004 | Preclinical animal study | Toxicology and Applied Pharmacology | In alloxan-induced diabetic rats, zinc chloride may protect against oxidative changes in the retina and pancreas at an early stage of diabetes. |
This is animal data only. No human studies were compiled.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN08899P | Peditrace Concentrate for Parenteral Infusion | Injection | Not stated |
| SIN15302P | Addaven Concentrate for Solution for Infusion | Infusion, solution concentrate | Not stated |
| SIN14341P | Nutritrace Concentrate for Solution for Infusion | Infusion, solution concentrate | Not stated |
All three registrations are valid single-ingredient licences, and none has been cancelled. All are injectable forms.
Safety Considerations
- Contraindication signals from the knowledge graph (not label text): methemoglobinemia, sulfhemoglobinemia, G6PD deficiency, glycogen storage disease, cystinuria, galactosemia, pyruvate dehydrogenase E3 deficiency, methemoglobinemia due to methemoglobin reductase deficiency, Wilson disease, iron metabolism disease, and hereditary hemochromatosis. These come from model-derived drug-disease edges and need confirmation against the package insert.
- Drug Interactions: 76 interactions were identified. Most are minor, including corticosteroids (hydrocortisone, prednisone, dexamethasone, budesonide and others) and several immunosuppressants and biologics. Moderate interactions were found with the tetracyclines (tetracycline, minocycline) and levofloxacin, likely through reduced absorption when chelated by zinc. This matters mainly for oral co-administration.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but there are no clinical trials and no human literature for severe nonproliferative diabetic retinopathy. The only related evidence is a single rat study for general diabetic retinopathy. The package insert warnings and indications are also unavailable, so safety screening cannot proceed.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website (blocking gap)
- Mechanism of action data from DrugBank
- A systematic literature search for zinc and diabetic retinopathy in humans
- A route compatibility assessment: the registered products are intravenous infusions, while the predicted eye conditions might need other routes, such as oral or topical delivery
- A review of the other predictions with a more plausible rationale, such as diabetic retinopathy (preclinical evidence), dry eye syndrome and acne. Several others, such as prolapse of lacrimal gland and brain aneurysm, have no clear mechanistic rationale and appear to be model artifacts.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.